Natural Grocers by Vitamin Cottage, Inc. (NYSE:NGVC) shares fell -0.77% in last trading session and ended the day at $20.59. NGVC Gross Margin is 29.20% and its has a return on assets of 7.50%. Natural Grocers by Vitamin Cottage, Inc. (NYSE:NGVC) quarterly performance is -18.81%.
Natural Grocers by Vitamin Cottage, Inc. (NYSE:NGVC) announced that the Company will release its first quarter fiscal year 2016 financial results after the market close on Thursday, January 28, 2016. Following the release via the wire services, the Company will host a conference call with financial analysts and investors from 2:30 to 3:15 p.m. Mountain Time (4:30 to 5:15 p.m. Eastern Time).
Prestige Brands Holdings, Inc. (NYSE:PBH) ended the last trading day at $47.03. Company weekly volatility is calculated as 3.50% and price to cash ratio as 111.75. Prestige Brands Holdings, Inc. (NYSE:PBH) showed a weekly performance of 2.39%.
Prestige Brands Holdings, Inc. (NYSE:PBH) announced that it will issue its fiscal 2016 third quarter earnings release on Thursday, February 4, 2016 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. EST.
On 20 January, J C Penney Company Inc (NYSE:JCP) shares fell -3.96% and was closed at $6.31. JCP EPS growth in last 5 year was -34.30%. J C Penney Company Inc (NYSE:JCP) year to date (YTD) performance is -5.26%.
J C Penney Company Inc (NYSE:JCP) US-based apparel and home furnishing retailers, has appointed Joe McFarland as executive vice president of stores, effective immediately.
BioScrip, Inc. (NASDAQ:BIOS) shares advanced 11.26% in last trading session and ended the day at $1.68. BIOS Gross Margin is 25.60% and its has a return on assets of -53.20%. BioScrip, Inc. (NASDAQ:BIOS) quarterly performance is 0.60%.
BioScrip, Inc. (NASDAQ:BIOS) provided an update on the Company’s progress implementing its Financial Improvement Plan to enhance shareholder value, improve financial flexibility and position BioScrip for success in 2016. As previously announced, the Company expects the Financial Improvement Plan to realize $35 million – $40 million in annualized net cost savings.
On 20 January, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares increased 3.90% and was closed at $1.60. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) year to date (YTD) performance is -44.44%.
On 11 January, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced the initiation of active patient recruitment in ENCORE-NF, a randomized, double-blind, placebo-controlled, Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor, in approximately 330 patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and stage 1 to 3 fibrosis using the NASH Clinical Research Network (CRN) Histologic Scoring System.